证券代码：002252 证券简称：上海莱士 公告编号：2025-047 上海莱士血液制品股份有限公司 关于控股股东增持公司股份进展暨权益变动触及 1%的公告 公司控股股东海盈康（青岛）医疗科技有限公司保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 上海莱士血液制品股份有限公司（"上海莱士"、"公司"）控股股东海盈 康（青岛）医疗科技有限公司（"海盈康"）基于对公司未来发展的信心和长期 投资价值的认同，增强投资者信心，计划自本次增持计划公告披露之日起6个月 内通过集中竞价交易方式增持公司股份，增持金额不低于人民币25,000万元，且 不超过人民币50,000万元（均含本数且不包含交易费用）（以下简称"本次增持 计划"）。具体内容详见公司于2025年5月22日披露的《关于控股股东增持股份 计划的公告》（公告编号：2025-043）。 公司于今日收到控股股东海盈康函告，获悉海盈康于2025年5月22日至2025 年6月19日期间，累计通过深圳证券交易所交易系统以集中竞价的方式增持公司 股份14,027,600 ...

Group 1 - Shengnuo Bio expects a net profit attributable to shareholders of 77.03 million to 94.14 million yuan for the first half of 2025, representing a year-on-year increase of 253.54% to 332.10% [1] - The significant growth in Shengnuo Bio's performance is primarily attributed to the strong performance of its peptide raw material business, which is closely related to GLP-1 formulations [1] Group 2 - Shanghai Laishi has completed the acquisition of 100% equity in Nanyue Bio for 4.2 billion yuan, with an additional contingent payment of 50 million yuan if the company processes 305 tons of plasma by 2025 [2] - The completion of the acquisition and registration marks a significant step forward in Shanghai Laishi's "plasma expansion" strategy, although it is expected to add substantial goodwill, raising concerns about future impairment risks [2] Group 3 - Beijing Saisheng Pharmaceutical has signed a new drug technology transfer agreement with its affiliate, transferring technology related to the NeoAB33 new drug project for a total of 20 million yuan [3] - The transfer may optimize the asset structure of Huada Protein, which reported a loss of 8.3 million yuan in 2024, while Saisheng Pharmaceutical reported a net profit of 39.97 million yuan in the first quarter of 2025, indicating its financial capability to advance research and development [3] Group 4 - Eli Lilly's reversible BTK inhibitor, Pirtobrutinib, has had its new indication application accepted for review in China, targeting patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received BTK inhibitor treatment [4] - If approved, Pirtobrutinib will provide a new treatment option for patients who have failed previous covalent BTK inhibitor therapies, further solidifying its market position in the treatment of B-cell malignancies [4] Group 5 - Innovent Biologics' CLDN-18.2 ADC product, IBI343, is proposed to be included as a breakthrough therapy for locally advanced or metastatic pancreatic cancer expressing CLDN 18.2, after at least two systemic treatments [5] - As the first CLDN18.2 ADC to achieve a breakthrough in pancreatic cancer, IBI343 is expected to fill a gap in second-line and later treatments, providing new options for patients [5]

Group 1 - The company Shanghai Laishi Blood Products Co., Ltd. signed an equity transfer agreement to acquire 100% equity of Nanyue Biological Pharmaceutical Co., Ltd. on March 26, 2025 [2] - The total consideration for the transaction is divided into a base consideration of 4.2 billion yuan and a contingent consideration of 50 million yuan if the company's plasma collection reaches 305 tons in 2025 [4] - The funding for the transaction will come from the company's own funds and self-raised funds [3] Group 2 - Nanyue Biological has completed the necessary business registration changes and obtained a new business license from the market supervision administration [5] - The company now holds 100% equity of Nanyue Biological, which has become a wholly-owned subsidiary, and will actively promote its daily operations and key projects [6]

证券代码：002252 证券简称：上海莱士 公告编号：2025-046 上海莱士血液制品股份有限公司 关于收购南岳生物制药有限公司 100%股权进展 暨完成工商变更登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、本次交易基本情况 上海莱士血液制品股份有限公司（以下简称"公司"或"上海莱士"）于 2025 年3月26日在湖南省衡阳市与刘令安、长沙德信生物技术合伙企业（有限合伙）、 陈玉、肖汉族、王香英及南岳生物制药有限公司（以下简称"南岳生物"或"标 的公司"）签署《关于南岳生物制药有限公司之股权转让协议》，收购该等转让 方合计持有的南岳生物 87.9766%股权；与湖南兴湘南岳私募基金合伙企业（有 限合伙）、湖南兴湘隆银高新产业投资合伙企业（有限合伙）及南岳生物签署《关 于南岳生物制药有限公司 12.0234%股权之股权转让协议》，收购湖南兴湘基金 合计持有的南岳生物 12.0234%股权（前述 87.9766%股权转让、12.0234%股权转 让合称"本次交易"）。 本次交易的资金来源为公司自有资金及自筹资金。 本次交易对价分为基础对价和或有 ...

Core Viewpoint - Shanghai Laishi Blood Products Co., Ltd. has made progress in acquiring a majority stake in Nanyue Biopharmaceutical Co., Ltd. and has received necessary approvals from foreign antitrust review agencies [1][2]. Group 1: Acquisition Details - The company signed an equity transfer agreement to acquire a total of 87.9766% of Nanyue Biopharmaceutical from Liu Ling'an and other parties [1]. - Additionally, the company signed an agreement to acquire 12.0234% of Nanyue Biopharmaceutical from Hunan Xingxiang Fund [1]. Group 2: Regulatory Approvals - The company has obtained all necessary approvals from foreign antitrust review agencies as required by local laws prior to the completion of the transaction [1]. Group 3: Transaction Status - The transaction has not yet been officially completed, and relevant work is currently in progress [2]. - The company will closely monitor the progress of the transaction and fulfill its information disclosure obligations in accordance with relevant laws and regulations [2].

公司已于近日获得了根据当地法律的规定需要在本次交易完成之前获得的 所有必要的境外反垄断审查机构的批准。 本次交易尚未正式交割，目前相关工作正在推进中。公司将密切关注本次交 易的进展，并按照相关法律法规的规定，及时履行信息披露义务，敬请广大投资 者理性投资，注意投资风险。 证券代码：002252 证券简称：上海莱士 公告编号：2025-045 上海莱士血液制品股份有限公司 关于通过境外反垄断审查 暨收购南岳生物制药有限公司股权的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、 完整，没有虚假记载、误导性陈述或重大遗漏。 2025 年 3 月 26 日，上海莱士血液制品股份有限公司（以下简称"公司"） 与刘令安、长沙德信生物技术合伙企业（有限合伙）、陈玉、肖汉族、王香英及 南岳生物制药有限公司（以下简称"南岳生物"）签署《关于南岳生物制药有限 公司之股权转让协议》，收购该等转让方合计持有的南岳生物 87.9766%股权； 与湖南兴湘南岳私募基金合伙企业（有限合伙）、湖南兴湘隆银高新产业投资合 伙企业（有限合伙）（以下合称"湖南兴湘基金"）及南岳生物签署《关于南岳 生物制药有限公司 12.0234%股 ...

Core Viewpoint - The control of blood product company Palin Bio (000403.SZ) has been transferred to China National Pharmaceutical Group (Sinopharm), which may lead to the integration of Palin Bio and Tian Tan Bio (600161.SH), potentially reshaping the competitive landscape in the blood product industry [1][5][9]. Group 1: Company Control and Financials - On June 10, Palin Bio announced that its controlling shareholder, Qiongcheng Shengbang Yinghao Investment Partnership, plans to transfer its entire 21.03% stake to China National Biotechnology Co., Ltd. [1] - The transaction is valued at 38.44 billion yuan, with a share price of 24.96 yuan, representing a 47% premium over the closing price of 16.96 yuan on June 6 [3]. - The estimated price-to-earnings ratio for this transaction is close to 32 times, based on a projected net profit of 7.45 billion yuan for 2024 [3][4]. Group 2: Industry Competition and Market Position - The integration of Tian Tan Bio and Palin Bio could lead to a combined revenue of approximately 86.87 billion yuan, surpassing Shanghai Lai Shi's (002252.SZ) projected revenue of 81.76 billion yuan for 2024 [7][15]. - If the integration occurs, the combined entity would control at least 123 plasma collection stations and have a total plasma collection volume of 4,181 tons, significantly increasing market share to nearly 30% [7][16]. - The blood product industry is experiencing consolidation due to limited new entrants since 2001, with companies increasingly acquiring others to expand market share [16][17]. Group 3: Challenges and Future Outlook - The integration process may face challenges, particularly regarding the internal conflicts within Palin Bio, especially with its second-largest shareholder, Harbin Tongzhi Cheng Technology Development Co., Ltd. [10][11][14]. - The future of the blood product industry may depend on how effectively China National Pharmaceutical Group can manage these internal dynamics while pursuing further consolidation [9][14]. - The industry is also exploring innovative solutions to reduce reliance on human plasma, with several companies making progress in developing recombinant products [21][22].

Group 1 - The core issue leading to the termination of major asset restructurings among listed companies is the inability to reach an agreement on key terms, particularly the transaction price [5][6][7] - Since 2025, over 20 listed companies have announced the failure of significant asset restructurings, including well-known firms such as Guozhong Water, China Merchants Energy, and Haier Biomedical [1][5] - Companies like Yuehongyuan A and *ST Shuangcheng have also faced similar issues, primarily due to disagreements on pricing [7][11] Group 2 - Market environment changes and prolonged negotiation periods have contributed to the abandonment of restructuring plans, as seen in cases like Xinno and Antong Holdings [9][10] - The complexity of transaction structures and the presence of asset ownership issues have also been significant factors in the failure of mergers and acquisitions [11][12] - The need for effective communication and coordination among parties involved in the transaction is crucial to avoid misunderstandings and ensure successful negotiations [17][19] Group 3 - Recent policy initiatives, such as the revised "Major Asset Restructuring Management Measures," aim to enhance the merger and acquisition market's activity and success rates [14][15] - Companies are encouraged to conduct thorough due diligence and risk assessments as foundational steps in the merger process [16] - Establishing a joint working group and regular communication mechanisms can help address disputes and facilitate smoother negotiations [18][19]

Core Viewpoint - The acquisition of a controlling stake in Pailin Biological by China National Pharmaceutical Group signifies a significant shift in ownership and control within the blood products industry in China, with implications for market competition and consolidation strategies [2][3]. Group 1: Acquisition Details - Pailin Biological's controlling shareholder, Shengbang Yinghao Investment Partnership, plans to transfer its entire 21.03% stake to China National Pharmaceutical for a total cash consideration of 3.844 billion yuan [1][3]. - The transaction values Pailin Biological at 24.96 yuan per share, representing a 47% premium over its closing price of 16.96 yuan on June 6 [3]. - The estimated price-to-earnings (P/E) ratio for this transaction is approximately 32 times, based on Pailin's projected net profit of 745 million yuan for 2024 [3]. Group 2: Industry Context - The valuation of Pailin Biological is notably higher than that of several other A-share blood product companies, which have P/E ratios around 25 times, with only Boya Bio reaching 36 times [4]. - The scarcity of blood products in China, due to regulatory restrictions on new production facilities since 2001, underpins the rationale for China National Pharmaceutical's substantial investment [5]. Group 3: Competitive Landscape - Following the acquisition, Tian Tan Biological, another player in the blood products sector, will face increased competition as both companies operate in the same industry [6]. - There are expectations that China National Pharmaceutical may integrate Pailin Biological into Tian Tan Biological, enhancing operational efficiency and market share [8]. - If the integration occurs, the combined entity would control at least 123 plasma collection stations, with a total collection volume exceeding 4,000 tons, significantly outpacing competitors like Shanghai Raist and Hualan Biological [8][9].

Economic Overview - In 2024, Shandong's GDP reached 98,565.8 billion yuan, growing by 5.7% year-on-year, with the primary, secondary, and tertiary industries contributing 6.7%, 40.2%, and 53.1% respectively [2] - The province's listed companies are crucial for economic development, focusing on green, low-carbon, and high-quality growth while enhancing technological innovation [2] Performance of Listed Companies - Shandong's listed companies achieved a total revenue of 2.95 trillion yuan in 2024, a year-on-year increase of 4.61%, while net profit was 175.9 billion yuan, down 3.20% [4] - 78.96% of the companies reported profits, which is 5.27 percentage points higher than the national average, indicating better performance despite challenges in traditional industries [4][5] Contribution to Economic Growth - Listed companies in Shandong contributed 29.92% of the province's GDP, with an added value of 705.18 billion yuan, reflecting their significant role in regional economic growth [5] - The labor productivity of listed companies was 483,600 yuan per person, 2.78 times the national average, showcasing their efficiency [5] Innovation and Growth of SMEs - In 2024, 67 companies on the Growth Enterprise Market reported revenues of 177.98 billion yuan, up 15.13%, and net profits of 11.74 billion yuan, up 49.42%, indicating strong growth in innovative SMEs [6] - The total R&D expenditure for these companies was 6.44 billion yuan, a 8.11% increase, highlighting their commitment to innovation [6] Market Capitalization and Value Management - By the end of 2024, the market capitalization of Shandong's listed companies reached 3.63 trillion yuan, a 4.18% increase, ranking seventh nationally [8] - 125 companies conducted share buybacks, totaling 9.568 billion yuan, reflecting a strong commitment to value management [8] Characteristics of Listed Companies - Private listed companies in Shandong accounted for 62.14% of the total, achieving revenues of 838.06 billion yuan, up 4.64%, and net profits of 431.87 billion yuan, up 16.49% [9][10] - Companies with overseas business generated 842.85 billion yuan in foreign income, a year-on-year increase of 8.89%, indicating the importance of international markets [12] Mergers and Acquisitions - In 2024, 13 listed companies in Shandong participated in mergers and acquisitions, with a total transaction value of 38.75 billion yuan, a 3.58-fold increase [14][15] - The trend of state-owned enterprises merging with peers is becoming more common, enhancing market competitiveness [15] Sustainable Development and ESG - Shandong's listed companies showed a 44.34% ESG report disclosure rate, slightly above the national average, indicating a growing recognition of sustainability [16][17] - The average ESG score for Shandong's companies was 5.79, higher than the national average, with two companies scoring above 9.00 [17] Innovation and Digital Transformation - R&D expenses for Shandong's listed companies reached 84.51 billion yuan, a 3.94% increase, with a focus on enhancing innovation capabilities [18] - The digital economy's core companies reported revenues of 330.38 billion yuan, up 27.57%, demonstrating significant growth in this sector [20] Traditional Industry Transformation - Traditional industries in Shandong are undergoing digital and intelligent transformations, with companies like Shandong High-Speed adopting advanced technologies to enhance operational efficiency [23] - The integration of digital and green technologies is seen as essential for fostering new productive forces in traditional sectors [24]